29 completed, 14 unknown, 5 terminated, 1 active not recruiting. 12 Phase 3, 11 Phase 1, 10 Not applicable, 9 Phase 2, 7 Phase 4.
Follow Central Retinal Vein Occlusion: new trials by email Literature Review of Central Retinal Vein Occlusion trials Research Report on Central Retinal Vein Occlusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products Faricimab, Port Delivery System with Ranibizumab - Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Active not recruiting | Hoffmann-La Roche | 6000 | 2022-11-21 | 2026-10-02 | |
| Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections Ophthalmologic exam at inclusion and 12 months after CRVO, Treatment standardization with aflibercept - Central Retinal Vein Occlusion | Not applicable | Completed | Fondation Ophtalmologique Adolphe de Rothschild | 60 | 2021-03-24 | 2025-04-30 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 729 | 2021-03-02 | 2024-08-06 |
| 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) 601 1.25mg, Ranibizuman 0.5 mg - Central Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-27 | 2025-06-27 |
| Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. Bevacizumab Ophthalmic and Intravitreal Dexamethasone., Bevacizumab Ophthalmic. - Central Retinal Vein Occlusion | Not applicable | Unknown | He Eye Hospital | 100 | 2020-10-17 | 2020-10-26 |
| Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy - Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | The Emmes Company, LLC | 16 | 2019-10-22 | 2024-12-02 |
| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection - Central Retinal Vein Occlusion | Phase 3 | Terminated | Novartis Pharmaceuticals | 493 | 2019-07-03 | 2023-01-30 |
| Surgical Stabilizer Assisted RVC With rtPA for CRVO Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg., Intravenous Infusion - Central Retinal Vein Occlusion | Phase 1 | Withdrawn | Universitaire Ziekenhuizen KU Leuven | 2018-10-16 | 2023-03-23 | |
| Phase I RVC With Ocriplasmin for CRVO Ocriplasmin intravenously - Central Retinal Vein Occlusion | Phase 1 | Completed | Universitaire Ziekenhuizen KU Leuven | 4 | 2016-12-01 | 2018-01-08 |
| Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Aflibercept (Eylea, BAY86-5321) - Central Retinal Vein Occlusion | Phase 4 | Completed | Bayer | 162 | 2016-06-10 | 2020-07-08 |
| Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Conbercept Ophthalmic Injection, sham injection - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Chengdu Kanghong Biotech Co., Ltd. | 242 | 2016-05-24 | 2022-07-13 |
| Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Aflibercept - Retinal Vein Occlusion, Diabetic Macular Edema | Phase 4 | Completed | Justis Ehlers | 31 | 2015-08-18 | 2021-05-12 |
| Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Hyperbaric chamber treatment - Central Retinal Vein Occlusion | Phase 2 | Unknown | Assaf-Harofeh Medical Center | 20 | 2015-03-01 | 2015-04-01 |
| Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Aflibercept, Ranibizumab - Central Retinal Vein Occlusion | Phase 4 | Completed | Anders Kvanta | 40 | 2014-10-01 | 2020-12-04 |
| Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) aflibercept, bevacizumab - Central Retinal Vein Occlusion | Phase 3 | Completed | The Emmes Company, LLC | 362 | 2014-09-01 | 2021-06-22 |
| Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study Free Eye Screenings, Enhanced Intervention, Usual Care - Glaucoma, Glaucoma Suspect | Not applicable | Completed | Wills Eye | 906 | 2014-09-01 | 2022-08-22 |
| Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I ziv-aflibercept drug - Age Related Macular Degeneration, Central Retinal Vein Occlusion | Phase 1 | Unknown | Rafic Hariri University Hospital | 100 | 2014-06-01 | 2014-06-25 |
| Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion ranibizumab - Macular Edema, Branch Retinal Vein Occlusion | Not applicable | Unknown | Tokyo Medical University | 100 | 2013-12-01 | 2014-06-23 |
| Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO Ranibizumab - Central Retinal Vein Occlusion | Not applicable | Unknown | Mie University | 30 | 2013-12-01 | 2014-03-19 |
Showing 20 of 51. Sign in to see all of them.
Retinal Vein Occlusion (51) · Macular Edema (17) · Vision Disorders (6) · Macular Degeneration (5) · Diabetic Retinopathy (3) · Retinal Artery Occlusion (3) · Glaucoma (2) · Calciphylaxis (1) · Cataract (1) · Choroidal Neovascularization (1) · Colitis, Ulcerative (1) · Communicable Diseases (1) · Craniocerebral Trauma (1) · Crohn Disease (1) · Depression (1)
Cardiovascular Diseases (51) · Embolism and Thrombosis (51) · Vascular Diseases (51) · Venous Thrombosis (51) · Eye Diseases (50) · Retinal Diseases (50) · Thrombosis (50) · Retinal Degeneration (22) · Macular Degeneration (17) · Pathological Conditions, Signs and Symptoms (10) · Neurologic Manifestations (8) · Signs and Symptoms (8) · Nervous System Diseases (7) · Sensation Disorders (7) · Pathologic Processes (4)
Ranibizumab (16) · aflibercept (9) · Bevacizumab (6) · Calcium Dobesilate (3) · Dexamethasone (3) · salicylhydroxamic acid (3) · Tissue Plasminogen Activator (2) · faricimab (2) · Anesthesia (1) · Anesthetics (1) · Anti-Inflammatory Agents (1) · Atorvastatin (1) · Gels (1) · Hemodilution (1) · Infusions, Intravenous (1)
Novartis Pharmaceuticals (4) · University of Toronto (3) · Anders Kvanta (2) · California Retina Consultants (2) · Hoffmann-La Roche (2) · The Emmes Company, LLC (2) · Universitaire Ziekenhuizen KU Leuven (2) · Aleris Helse (1) · Asociación para Evitar la Ceguera en México (1) · Assaf-Harofeh Medical Center (1) · Bayer (1) · Centre Hospitalier Intercommunal Creteil (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Fovea Pharmaceuticals SA (1)
United States (21) · Canada (7) · France (7) · China (6) · United Kingdom (6) · Australia (5) · Germany (5) · Israel (5) · Italy (5) · Japan (5) · Spain (5) · Sweden (5) · Czechia (4) · Denmark (4) · Hungary (4)
Ahmad Mansour, MD (1) · Alain Gaudric, MD (1) · Anders Kvanta, MD, PhD (1) · Baruch D Kuppermann,, M.D., Ph.D. (1) · Bettina Kinge, MD DMSc (1) · Carmen Gonzalez-Mijares, Physician (1) · Chris Hudson, OD, PhD (1) · Christopher Hudson, PhD (1) · Dante J Pieramici, M.D. (1) · Dante J Pieramici, MD (1) · David Wong, MD (1) · Emmanuel E Pazo, M.D., Ph.D. (1)
PMID 20591399, PMID 22960949, PMID 24729079, PMID 25677668, PMID 27409478, PMID 28492910, PMID 28673747, PMID 30770354, PMID 31047340, PMID 31169862, PMID 31600368, PMID 31757691, PMID 33415354, PMID 33556381, PMID 34014814, PMID 34709363, PMID 34934034, PMID 35461831, PMID 36584835, PMID 36912792, PMID 37220815, PMID 37943541, PMID 38280653, PMID 40107501, PMID 40886069, PMID 42753135
1UG1EY026876-01A1 (1), 1UG1EY028517-01 (1), 2009 (1), 2014 (1), 2018 (1), U10EY023521 (1), U10EY023529 (1), U10EY023533 (1)